查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1976591

造影劑市場：依藥物類型、給藥方式、應用、最終用戶和通路分類－2026-2032年全球預測

Imaging Agents Market by Agent Type, Modality, Application, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 193 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，成像劑市場價值將達到 107.6 億美元，到 2026 年將成長到 114 億美元，到 2032 年將達到 169.9 億美元，複合年成長率為 6.73%。

主要市場統計數據
基準年 2025 107.6億美元
預計年份：2026年 114億美元
預測年份 2032 169.9億美元
複合年成長率 (%) 6.73%

本導言闡述了不斷變化的臨床需求、技術融合以及法規環境的變化如何重塑全球造影劑生態系統。

診斷影像領域處於臨床需求、技術進步和監管的交匯點，使其成為整個診斷流程創新的焦點。隨著患者群體老化以及疾病檢測模式向更早期、更精準的方法轉變，製藥、診斷和醫療服務領域的相關人員正在重新調整優先事項，以滿足日益成長的安全性、特異性和工作流程效率方面的期望。分子成像技術的進步、超音波造影技術的超音波以及人們對放射性藥物日益成長的興趣，都在拓展診斷能力的同時，也為生產、分銷和報銷系統帶來了新的複雜性。

分析美國於 2025 年實施的關稅措施所帶來的累積營運、採購和商業性影響以及供應鏈後果。

2025年實施的關稅措施對造影劑供應鏈產生了多方面的影響，從組件採購到臨床應用，各個環節都受到了波及。進口原料和成品關稅的提高，使得依賴跨境供應鏈取得造影劑前驅物、放射性核種組件和專用包裝材料的製造商的採購流程變得更加複雜。因此，各機構正在加速評估替代籌資策略，例如在地採購、多元化採購和策略儲備，以降低供應中斷的風險。

詳細的細分分析解釋了藥物類型、成像方式、臨床應用、最終用戶和分銷管道如何為每個相關人員創造不同的策略需求。

基於細分的分析揭示了每種造影劑、成像方式、臨床應用、終端用戶和分銷模式所面臨的不同機會和挑戰。依藥物類型分析顯示，钆基造影劑、碘基造影劑、微氣泡造影劑和放射性藥物呈現不同的發展趨勢。特別是放射性藥物，又可進一步細分為PET和SPECT途徑，需要專門的生產流程和監管。這種多樣性要求針對每類藥物獨特的穩定性、操作特性和監管要求，制定量身訂製的研發策略和生產投資。

區域洞察，提供對重點區域成像劑採用趨勢的詳細分析：揭示每個主要區域不同的法規結構、臨床重點和基礎設施能力如何影響成像劑的採用。

區域趨勢正在顯著影響美洲、歐洲、中東和非洲以及亞太地區的應用模式、監管方式和商業策略。在美洲，學術醫療中心和綜合醫療保健系統的集中正在加速先進示蹤劑和基於價值的影像方法的應用。同時，供應鏈韌性和報銷談判仍然是商業領域關注的核心議題。美洲的監管環境將嚴格的安全監測與針對特定適應症的加速臨床導入途徑結合，促使製造商調整證據產生以符合支付方的期望。

關鍵的競爭考察和策略性公司洞察，展示了製造、夥伴關係、分銷和數位化整合的能力如何決定市場定位和差異化。

主要企業之間的競爭動態揭示了影響產業發展方向的若干策略重點。在放射化學、契約製造和法規遵循方面擁有深厚實力的公司，能夠更好地滿足市場對放射性藥物的獨特需求。同時，專注於傳統造影劑的公司正透過改進配方和加強上市後監測來解決安全性和耐受性問題。策略夥伴關係和聯盟模式日益普遍，推動了技術轉移、合作臨床開發和聯合商業化等舉措，從而在控制資本密集度的同時，實現市場擴張。

我們為產業領導者提出的具體策略建議著重於加強供應鏈韌性、有針對性的研發、建立夥伴關係關係、與報銷機制保持一致以及提供證據以推動永續成長。

產業領導者可以採取切實可行的策略行動，以應對不斷變化的臨床需求、日益複雜的監管以及供應鏈壓力。首先，投資於具有韌性的價值鏈結構，包括區域性製造地和多元化的採購管道，可以降低受貿易政策波動和物流中斷影響的風險。其次，研發工作應優先考慮安全性改進和臨床差異化，從而確保符合監管要求，並透過改善患者預後和更清晰的價值提案來促進臨床應用。

本研究採用一手和二手調查方法、專家檢驗和三角測量調查方法，以獲得穩健而實用的市場見解。

本分析的調查方法結合了定性和定量方法，旨在提供可靠且實用的見解。初步調查包括對參與造影劑研發、生產和分銷的臨床負責人、監管專家、採購專員和商業高管進行結構化訪談。這些訪談提供了關於臨床應用促進因素、供應鏈挑戰以及近期政策變化對商業影響的第一手觀點。

總之，我們整合了技術創新、安全優先事項和供應鏈調整如何塑造造影劑價值鏈中所有相關人員的策略需求。

總之，造影劑產業的特點是技術快速發展、安全期望不斷提高，以及供應鏈和政策趨勢帶來的不斷變化的商業性壓力。這些因素既給製造商、經銷商、臨床用戶和支付方帶來了挑戰，也帶來了機會。積極投資於更安全的化學成分、供應鏈韌性和整合診斷解決方案的機構，將更有能力滿足臨床醫生的需求，並在競爭激烈的市場環境中脫穎而出。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：造影市場－依造影劑類型分類

  • 钆基造影劑
  • 碘造影劑
  • 微氣泡造影劑
  • 放射性藥物
    • PET造影劑
    • SPECT造影劑

第9章：造影劑市場：依影像方式分類

  • 電腦斷層掃描
  • 磁振造影
  • 核子醫學掃描術診斷
  • 超音波影像

第10章：造影劑市場：依應用領域分類

  • 心臟病學
  • 胃腸病學
  • 肌肉骨骼系統
  • 神經病學
  • 腫瘤學

第11章造影劑市場：依最終用戶分類

  • 學術研究機構
  • 門診手術中心
  • 診斷檢查室
  • 醫院和診斷影像中心

第12章：造影劑市場：依通路分類

  • 離線
  • 線上

第13章：造影市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章造影劑市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章：造影劑市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章：美國造影市場

第17章：中國造影劑市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Bayer AG
  • Bracco Imaging SpA
  • Cardinal Health, Inc.
  • Fujifilm Holdings Corporation
  • GE Healthcare
  • Guerbet SA
  • JB Chemicals & Pharmaceuticals Limited
  • Lantheus Holdings, Inc.
  • Livealth Biopharma
  • Mallinckrodt plc
  • Sagent Pharmaceuticals, Inc.
  • Scintica Instrumentation, Inc.
  • Siemens Healthineers AG
Product Code: MRR-69324464D0E7

The Imaging Agents Market was valued at USD 10.76 billion in 2025 and is projected to grow to USD 11.40 billion in 2026, with a CAGR of 6.73%, reaching USD 16.99 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 10.76 billion
Estimated Year [2026] USD 11.40 billion
Forecast Year [2032] USD 16.99 billion
CAGR (%) 6.73%

Introduction describing how evolving clinical demands, technological convergence, and regulatory dynamics are reshaping the global imaging agents ecosystem

The landscape of imaging agents sits at the intersection of clinical need, technological progress, and regulatory scrutiny, making it a focal point for innovation across diagnostic pathways. As patient populations age and disease detection paradigms shift toward earlier and more precise modalities, stakeholders across pharma, diagnostics, and healthcare delivery are recalibrating priorities to align with heightened expectations for safety, specificity, and workflow efficiency. Advancements in molecular imaging, improvements in ultrasound contrast technologies, and renewed interest in radiopharmaceuticals are converging to broaden diagnostic capabilities while also introducing new complexities in manufacturing, distribution, and reimbursement.

Across clinical specialties, imaging agents now play a central role not only in diagnosis but also in treatment planning and therapy monitoring. This expanded utility elevates demands on clinical validation, post-market surveillance, and interoperability with imaging platforms. In response, manufacturers and clinical partners are investing in evidence generation, standardized protocols, and digital tools that enhance image quantitation and reporting. Consequently, the ecosystem is evolving from a product-centric model toward integrated diagnostic solutions that combine agents, instrumentation, and analytics to deliver higher-value clinical outcomes.

The imaging agents sector is undergoing transformative shifts driven by technological innovation, heightened safety expectations, and a rapidly evolving regulatory environment. Molecular imaging advances are enabling greater target specificity, which in turn supports precision medicine approaches and more nuanced patient stratification. Concurrently, concerns about contrast safety-particularly around long-term retention and nephrotoxicity-have elevated the importance of agent chemistries and post-market data, prompting manufacturers to prioritize safer formulations and to invest in comparative clinical studies.

Technological convergence is another defining trend: hybrid imaging systems and enhanced image processing algorithms are increasing the diagnostic yield of established agents while stimulating demand for new tracers and contrast media optimized for quantitative imaging. In parallel, digital health tools, including AI-driven image analysis and cloud-based workflows, are changing how imaging agents are used in care pathways and research. These shifts are forcing traditional players to adopt cross-disciplinary strategies, forging partnerships with device manufacturers, software innovators, and clinical research organizations to maintain competitiveness and to deliver integrated solutions across clinical settings.

Analysis of the cumulative operational, procurement, and commercial effects stemming from the United States tariff measures enacted in 2025 and their supply chain consequences

The imposition of tariff measures in 2025 has produced a multifaceted impact on the imaging agents supply chain, creating ripple effects that extend from component sourcing to clinical deployment. Increased duties on imported raw materials and finished agents have elevated procurement complexity for manufacturers that rely on cross-border supply chains for contrast media precursors, radionuclide components, and specialized packaging materials. As a result, organizations have accelerated evaluations of alternative sourcing strategies, including local suppliers, multi-sourcing frameworks, and strategic stockpiling to mitigate disruption risks.

These trade policy changes have also influenced commercial dynamics. Healthcare providers and distributors are reassessing contract terms and pricing structures to manage margin pressures while maintaining service levels. Payers and hospital procurement teams are emphasizing cost-effectiveness and supply resiliency when selecting agents and vendors, prompting suppliers to demonstrate operational flexibility and value beyond unit pricing. In addition, regulatory and customs processes have required closer coordination, with firms enhancing compliance capabilities and logistics planning to reduce lead times and preserve continuity of care. Collectively, these adaptations underscore an industry-wide emphasis on supply chain robustness, collaborative contracting, and strategic operational agility.

In-depth segmentation insights explaining how agent types, imaging modalities, clinical applications, end users, and distribution channels create distinct strategic imperatives for stakeholders

Segmentation-based insights reveal differentiated opportunities and challenges across agent types, imaging modalities, clinical applications, end users, and distribution models. When analyzed by agent type, trends show distinct trajectories for gadolinium-based agents, iodinated contrast agents, microbubble agents, and radiopharmaceuticals, with radiopharmaceuticals further delineated into PET and SPECT pathways that demand specialized manufacturing and regulatory oversight. This diversity necessitates tailored R&D strategies and manufacturing investments to address the unique stability, handling, and regulatory profiles of each category.

From a modality perspective, computed tomography, magnetic resonance imaging, nuclear imaging, and ultrasound imaging each present different clinical and operational imperatives. Nuclear imaging requires close integration with PET and SPECT infrastructures and radiopharmacy networks, while ultrasound innovations encompass both two-dimensional and three-dimensional contrast agent applications that are more accessible in point-of-care environments. Clinical application segmentation highlights the varying agent requirements across cardiology, gastroenterology, musculoskeletal, neurology, and oncology, with oncology and neurology generally driving demand for higher specificity agents and more rigorous validation.

End-user segmentation illustrates how academic research institutes, ambulatory surgical centers, diagnostic laboratories, and hospitals and imaging centers adopt and deploy agents differently, with research institutions often prioritizing novel tracers and hospitals focusing on operational reliability and throughput. Distribution channel segmentation, spanning direct sales, distributors, and online retail, underscores the strategic importance of distribution partners; distributors themselves are differentiated into international and local distributors, each offering distinct reach, regulatory familiarity, and logistical capabilities that must be matched to product profiles and customer needs.

Key regional insights detailing how distinct regulatory frameworks, clinical priorities, and infrastructure capacities are influencing imaging agent adoption across major global regions

Regional dynamics shape adoption patterns, regulatory approaches, and commercial strategies in meaningful ways across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, a concentration of academic medical centers and integrated healthcare systems accelerates adoption of advanced tracers and value-based imaging approaches, while supply chain resilience and reimbursement negotiations remain central commercial concerns. The regulatory landscape in the Americas combines rigorous safety oversight with pathways for accelerated clinical adoption in select indications, prompting manufacturers to align evidence generation with payer expectations.

Europe, Middle East & Africa presents a heterogeneous set of regulatory regimes and healthcare delivery models, where centralized regulatory frameworks coexist with country-specific reimbursement and procurement mechanisms. This complexity rewards companies that invest in localized regulatory strategy and regionally tailored clinical programs. In the Asia-Pacific region, market dynamics are characterized by rapid infrastructure expansion, growing clinical research capacity, and an increasing emphasis on point-of-care imaging solutions. Local manufacturing capabilities and regional distribution partnerships are pivotal for scaling adoption, especially as clinical demand diversifies across oncology, cardiology, and neurology applications. Collectively, regional insights point to the importance of adaptive regulatory strategies, localized partnerships, and differentiated commercial approaches.

Key competitive and strategic company insights outlining how capabilities in manufacturing, partnerships, distribution, and digital integration are determining market positioning and differentiation

Competitive dynamics among leading organizations reveal several strategic priorities that are shaping the sector's trajectory. Companies with deep capabilities in radiochemistry, contract manufacturing, and regulatory affairs are positioned to capitalize on the specialized demands of radiopharmaceuticals, whereas firms focused on conventional contrast media are responding to safety and tolerability concerns through reformulation and enhanced post-market surveillance. Strategic partnerships and alliance models are increasingly common, enabling technology transfer, shared clinical development, and co-commercialization arrangements that extend market reach while managing capital intensity.

Manufacturers are also diversifying distribution strategies, balancing direct sales with distributor partnerships to optimize access across hospitals, diagnostic centers, and ambulatory settings. Concurrently, investment in quality systems, cold-chain logistics for temperature-sensitive agents, and compliance capabilities has become a competitive differentiator. In addition, a subset of actors is prioritizing the integration of digital tools and analytics to add demonstrable clinical value, improve imaging workflow efficiency, and support outcomes-based contracting discussions with payers. These trends indicate that success will favor organizations that combine technical excellence with operational flexibility and evidence-driven commercialization models.

Actionable strategic recommendations for industry leaders focused on supply chain resilience, targeted R&D, partnerships, reimbursement alignment, and evidence generation to drive sustainable growth

Industry leaders can pursue a practical set of strategic actions to navigate evolving clinical needs, regulatory complexity, and supply chain pressures. First, investing in resilient supply chain architectures, including regional manufacturing hubs and multi-sourced procurement, reduces vulnerability to trade policy shocks and logistical disruption. Second, aligning R&D priorities with safety enhancements and clinical differentiation helps address regulatory scrutiny and strengthens clinical adoption by delivering better patient outcomes and clearer value propositions.

Third, forming targeted alliances with device manufacturers, clinical research organizations, and digital health vendors accelerates the development of integrated diagnostic solutions that combine agents with imaging platforms and analytics. Fourth, cultivating payer engagement and designing evidence packages that demonstrate clinical utility and cost-effectiveness facilitate smoother reimbursement pathways. Fifth, optimizing distribution strategies by combining direct engagement in major accounts with partnerships for regional reach ensures operational efficiency and market coverage. Finally, enhancing post-market surveillance, real-world evidence generation, and clinician education programs builds trust with end users and supports long-term adoption across diverse clinical settings.

Research methodology describing the multi-source primary and secondary approaches, expert validation, and triangulation techniques used to derive robust, actionable market insights

The research methodology underpinning this analysis combined qualitative and quantitative approaches designed to deliver robust, actionable insights. Primary research included structured interviews with clinical leaders, regulatory experts, procurement specialists, and commercial executives involved in imaging agent development, manufacturing, and distribution. These interviews provided first-hand perspectives on clinical adoption drivers, supply chain challenges, and the commercial implications of recent policy changes.

Secondary research encompassed systematic review of regulatory filings, clinical trial registries, patent literature, and peer-reviewed publications to contextualize technological trends and safety considerations. In addition, supply chain mapping and logistics data were analyzed to understand the operational implications of tariff changes and to identify critical nodes of vulnerability. Findings were triangulated across data sources and validated through expert workshops, ensuring consistency and relevancy. Finally, methodological limitations and areas of uncertainty were documented, with transparency around data sources and assumptions to support informed decision-making by stakeholders.

Conclusion synthesizing how technological innovation, safety priorities, and supply chain adaptations will shape strategic imperatives for all stakeholders across the imaging agents value chain

In conclusion, the imaging agents landscape is characterized by rapid technological progress, intensifying safety expectations, and evolving commercial pressures driven by supply chain and policy dynamics. These forces are creating both challenges and opportunities for manufacturers, distributors, clinical users, and payers. Organizations that proactively invest in safer chemistries, supply chain resilience, and integrated diagnostic solutions are better positioned to meet clinician needs and to differentiate in increasingly competitive procurement environments.

Moving forward, success will hinge on cross-functional collaboration that links scientific innovation with pragmatic operational and commercial strategies. By prioritizing evidence generation, regulatory engagement, and strategic partnerships, stakeholders can accelerate clinical adoption while managing the operational complexities introduced by trade policy shifts and regional regulatory variance. Ultimately, a balanced focus on clinical value, operational robustness, and commercial adaptability will define which actors lead the next phase of evolution in imaging agents.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Imaging Agents Market, by Agent Type

  • 8.1. Gadolinium Based Agents
  • 8.2. Iodinated Contrast Agents
  • 8.3. Microbubble Agents
  • 8.4. Radiopharmaceuticals
    • 8.4.1. Pet Imaging Agents
    • 8.4.2. Spect Imaging Agents

9. Imaging Agents Market, by Modality

  • 9.1. Computed Tomography
  • 9.2. Magnetic Resonance Imaging
  • 9.3. Nuclear Imaging
  • 9.4. Ultrasound Imaging

10. Imaging Agents Market, by Application

  • 10.1. Cardiology
  • 10.2. Gastroenterology
  • 10.3. Musculoskeletal
  • 10.4. Neurology
  • 10.5. Oncology

11. Imaging Agents Market, by End User

  • 11.1. Academic Research Institutes
  • 11.2. Ambulatory Surgical Centers
  • 11.3. Diagnostic Laboratories
  • 11.4. Hospitals And Imaging Centers

12. Imaging Agents Market, by Distribution Channel

  • 12.1. Offline
  • 12.2. Online

13. Imaging Agents Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Imaging Agents Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Imaging Agents Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Imaging Agents Market

17. China Imaging Agents Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Bayer AG
  • 18.6. Bracco Imaging S.p.A.
  • 18.7. Cardinal Health, Inc.
  • 18.8. Fujifilm Holdings Corporation
  • 18.9. GE Healthcare
  • 18.10. Guerbet S.A.
  • 18.11. J. B. Chemicals & Pharmaceuticals Limited
  • 18.12. Lantheus Holdings, Inc.
  • 18.13. Livealth Biopharma
  • 18.14. Mallinckrodt plc
  • 18.15. Sagent Pharmaceuticals, Inc.
  • 18.16. Scintica Instrumentation, Inc.
  • 18.17. Siemens Healthineers AG

LIST OF FIGURES

  • FIGURE 1. GLOBAL IMAGING AGENTS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL IMAGING AGENTS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL IMAGING AGENTS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL IMAGING AGENTS MARKET SIZE, BY AGENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL IMAGING AGENTS MARKET SIZE, BY MODALITY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL IMAGING AGENTS MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL IMAGING AGENTS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL IMAGING AGENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL IMAGING AGENTS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL IMAGING AGENTS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL IMAGING AGENTS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES IMAGING AGENTS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA IMAGING AGENTS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL IMAGING AGENTS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL IMAGING AGENTS MARKET SIZE, BY AGENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL IMAGING AGENTS MARKET SIZE, BY GADOLINIUM BASED AGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL IMAGING AGENTS MARKET SIZE, BY GADOLINIUM BASED AGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL IMAGING AGENTS MARKET SIZE, BY GADOLINIUM BASED AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL IMAGING AGENTS MARKET SIZE, BY IODINATED CONTRAST AGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL IMAGING AGENTS MARKET SIZE, BY IODINATED CONTRAST AGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL IMAGING AGENTS MARKET SIZE, BY IODINATED CONTRAST AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL IMAGING AGENTS MARKET SIZE, BY MICROBUBBLE AGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL IMAGING AGENTS MARKET SIZE, BY MICROBUBBLE AGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL IMAGING AGENTS MARKET SIZE, BY MICROBUBBLE AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL IMAGING AGENTS MARKET SIZE, BY RADIOPHARMACEUTICALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL IMAGING AGENTS MARKET SIZE, BY RADIOPHARMACEUTICALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL IMAGING AGENTS MARKET SIZE, BY RADIOPHARMACEUTICALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL IMAGING AGENTS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL IMAGING AGENTS MARKET SIZE, BY PET IMAGING AGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL IMAGING AGENTS MARKET SIZE, BY PET IMAGING AGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL IMAGING AGENTS MARKET SIZE, BY PET IMAGING AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL IMAGING AGENTS MARKET SIZE, BY SPECT IMAGING AGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL IMAGING AGENTS MARKET SIZE, BY SPECT IMAGING AGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL IMAGING AGENTS MARKET SIZE, BY SPECT IMAGING AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL IMAGING AGENTS MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL IMAGING AGENTS MARKET SIZE, BY COMPUTED TOMOGRAPHY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL IMAGING AGENTS MARKET SIZE, BY COMPUTED TOMOGRAPHY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL IMAGING AGENTS MARKET SIZE, BY COMPUTED TOMOGRAPHY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL IMAGING AGENTS MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL IMAGING AGENTS MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL IMAGING AGENTS MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL IMAGING AGENTS MARKET SIZE, BY NUCLEAR IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL IMAGING AGENTS MARKET SIZE, BY NUCLEAR IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL IMAGING AGENTS MARKET SIZE, BY NUCLEAR IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL IMAGING AGENTS MARKET SIZE, BY ULTRASOUND IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL IMAGING AGENTS MARKET SIZE, BY ULTRASOUND IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL IMAGING AGENTS MARKET SIZE, BY ULTRASOUND IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL IMAGING AGENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL IMAGING AGENTS MARKET SIZE, BY CARDIOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL IMAGING AGENTS MARKET SIZE, BY CARDIOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL IMAGING AGENTS MARKET SIZE, BY CARDIOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL IMAGING AGENTS MARKET SIZE, BY GASTROENTEROLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL IMAGING AGENTS MARKET SIZE, BY GASTROENTEROLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL IMAGING AGENTS MARKET SIZE, BY GASTROENTEROLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL IMAGING AGENTS MARKET SIZE, BY MUSCULOSKELETAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL IMAGING AGENTS MARKET SIZE, BY MUSCULOSKELETAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL IMAGING AGENTS MARKET SIZE, BY MUSCULOSKELETAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL IMAGING AGENTS MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL IMAGING AGENTS MARKET SIZE, BY NEUROLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL IMAGING AGENTS MARKET SIZE, BY NEUROLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL IMAGING AGENTS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL IMAGING AGENTS MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL IMAGING AGENTS MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL IMAGING AGENTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL IMAGING AGENTS MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL IMAGING AGENTS MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL IMAGING AGENTS MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL IMAGING AGENTS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL IMAGING AGENTS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL IMAGING AGENTS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL IMAGING AGENTS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL IMAGING AGENTS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL IMAGING AGENTS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL IMAGING AGENTS MARKET SIZE, BY HOSPITALS AND IMAGING CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL IMAGING AGENTS MARKET SIZE, BY HOSPITALS AND IMAGING CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL IMAGING AGENTS MARKET SIZE, BY HOSPITALS AND IMAGING CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL IMAGING AGENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL IMAGING AGENTS MARKET SIZE, BY OFFLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL IMAGING AGENTS MARKET SIZE, BY OFFLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL IMAGING AGENTS MARKET SIZE, BY OFFLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL IMAGING AGENTS MARKET SIZE, BY ONLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL IMAGING AGENTS MARKET SIZE, BY ONLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL IMAGING AGENTS MARKET SIZE, BY ONLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL IMAGING AGENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. AMERICAS IMAGING AGENTS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 73. AMERICAS IMAGING AGENTS MARKET SIZE, BY AGENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 74. AMERICAS IMAGING AGENTS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 75. AMERICAS IMAGING AGENTS MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 76. AMERICAS IMAGING AGENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 77. AMERICAS IMAGING AGENTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 78. AMERICAS IMAGING AGENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 79. NORTH AMERICA IMAGING AGENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. NORTH AMERICA IMAGING AGENTS MARKET SIZE, BY AGENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 81. NORTH AMERICA IMAGING AGENTS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 82. NORTH AMERICA IMAGING AGENTS MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 83. NORTH AMERICA IMAGING AGENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 84. NORTH AMERICA IMAGING AGENTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 85. NORTH AMERICA IMAGING AGENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 86. LATIN AMERICA IMAGING AGENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. LATIN AMERICA IMAGING AGENTS MARKET SIZE, BY AGENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 88. LATIN AMERICA IMAGING AGENTS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 89. LATIN AMERICA IMAGING AGENTS MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 90. LATIN AMERICA IMAGING AGENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 91. LATIN AMERICA IMAGING AGENTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 92. LATIN AMERICA IMAGING AGENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 93. EUROPE, MIDDLE EAST & AFRICA IMAGING AGENTS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 94. EUROPE, MIDDLE EAST & AFRICA IMAGING AGENTS MARKET SIZE, BY AGENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 95. EUROPE, MIDDLE EAST & AFRICA IMAGING AGENTS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 96. EUROPE, MIDDLE EAST & AFRICA IMAGING AGENTS MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 97. EUROPE, MIDDLE EAST & AFRICA IMAGING AGENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 98. EUROPE, MIDDLE EAST & AFRICA IMAGING AGENTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 99. EUROPE, MIDDLE EAST & AFRICA IMAGING AGENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPE IMAGING AGENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPE IMAGING AGENTS MARKET SIZE, BY AGENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPE IMAGING AGENTS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE IMAGING AGENTS MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPE IMAGING AGENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPE IMAGING AGENTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE IMAGING AGENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 107. MIDDLE EAST IMAGING AGENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. MIDDLE EAST IMAGING AGENTS MARKET SIZE, BY AGENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 109. MIDDLE EAST IMAGING AGENTS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 110. MIDDLE EAST IMAGING AGENTS MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 111. MIDDLE EAST IMAGING AGENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 112. MIDDLE EAST IMAGING AGENTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 113. MIDDLE EAST IMAGING AGENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 114. AFRICA IMAGING AGENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. AFRICA IMAGING AGENTS MARKET SIZE, BY AGENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 116. AFRICA IMAGING AGENTS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 117. AFRICA IMAGING AGENTS MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 118. AFRICA IMAGING AGENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 119. AFRICA IMAGING AGENTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 120. AFRICA IMAGING AGENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 121. ASIA-PACIFIC IMAGING AGENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 122. ASIA-PACIFIC IMAGING AGENTS MARKET SIZE, BY AGENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 123. ASIA-PACIFIC IMAGING AGENTS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 124. ASIA-PACIFIC IMAGING AGENTS MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 125. ASIA-PACIFIC IMAGING AGENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 126. ASIA-PACIFIC IMAGING AGENTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 127. ASIA-PACIFIC IMAGING AGENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL IMAGING AGENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 129. ASEAN IMAGING AGENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. ASEAN IMAGING AGENTS MARKET SIZE, BY AGENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 131. ASEAN IMAGING AGENTS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 132. ASEAN IMAGING AGENTS MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 133. ASEAN IMAGING AGENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 134. ASEAN IMAGING AGENTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 135. ASEAN IMAGING AGENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 136. GCC IMAGING AGENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 137. GCC IMAGING AGENTS MARKET SIZE, BY AGENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 138. GCC IMAGING AGENTS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 139. GCC IMAGING AGENTS MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 140. GCC IMAGING AGENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 141. GCC IMAGING AGENTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 142. GCC IMAGING AGENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPEAN UNION IMAGING AGENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPEAN UNION IMAGING AGENTS MARKET SIZE, BY AGENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPEAN UNION IMAGING AGENTS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPEAN UNION IMAGING AGENTS MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPEAN UNION IMAGING AGENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPEAN UNION IMAGING AGENTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPEAN UNION IMAGING AGENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 150. BRICS IMAGING AGENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 151. BRICS IMAGING AGENTS MARKET SIZE, BY AGENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 152. BRICS IMAGING AGENTS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 153. BRICS IMAGING AGENTS MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 154. BRICS IMAGING AGENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 155. BRICS IMAGING AGENTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 156. BRICS IMAGING AGENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 157. G7 IMAGING AGENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 158. G7 IMAGING AGENTS MARKET SIZE, BY AGENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 159. G7 IMAGING AGENTS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 160. G7 IMAGING AGENTS MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 161. G7 IMAGING AGENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 162. G7 IMAGING AGENTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 163. G7 IMAGING AGENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 164. NATO IMAGING AGENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 165. NATO IMAGING AGENTS MARKET SIZE, BY AGENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 166. NATO IMAGING AGENTS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 167. NATO IMAGING AGENTS MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 168. NATO IMAGING AGENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 169. NATO IMAGING AGENTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 170. NATO IMAGING AGENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 171. GLOBAL IMAGING AGENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 172. UNITED STATES IMAGING AGENTS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 173. UNITED STATES IMAGING AGENTS MARKET SIZE, BY AGENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 174. UNITED STATES IMAGING AGENTS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 175. UNITED STATES IMAGING AGENTS MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 176. UNITED STATES IMAGING AGENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 177. UNITED STATES IMAGING AGENTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 178. UNITED STATES IMAGING AGENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 179. CHINA IMAGING AGENTS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 180. CHINA IMAGING AGENTS MARKET SIZE, BY AGENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 181. CHINA IMAGING AGENTS MARKET SIZE, BY RADIOPHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 182. CHINA IMAGING AGENTS MARKET SIZE, BY MODALITY, 2018-2032 (USD MILLION)
  • TABLE 183. CHINA IMAGING AGENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 184. CHINA IMAGING AGENTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 185. CHINA IMAGING AGENTS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)